mail2

Posts tagged: treatment

BACKGROUND: Neuromyelitis optica (NMO) is a severe autoimmune disease targeting optic nerves and spinal cord. The monoclonal anti-CD20 B-cell antibody rituximab is an emerging therapeutic option in NMO. However, neither long-term efficacy or safety of rituximab, nor the correlation between B-cell counts, B-cell fostering cytokines, aquaporin-4 antibodies (AQP4-ab), and disease activity in NMO, have been investigated prospectively


Neuromyelitis optica is a central nervous system disease characterized by optic neuritis and transverse myelitis. It is a devastating illness, and early treatment may prevent future relapses and severe disability. However, there is much variability in protocols used for treatment.


The authors report a case of a 16-year-old girl with a history of systemic lupus erythematosus who developed bilateral acute optic neuritis.


Objective: Movement disorders (MD) have been described in demyelinating diseases, especially in multiple sclerosis (MS). Paroxysmal dystonia, also called tonic spasm (TS) is the most frequent MD in MS. Only few cases have been reported in Neuromyelitis optica (NMO) albeit it’s frequently referred by these patients


Objetive: To demonstrate the occurrence of intractable hiccup and nausea (IHN) as first symptoms in Neuromyelitis optica (NMO) patients who developed cervical myelitis. Background: IHN are unique symptoms of NMO, which is a neurological disorder mainly characterized by optic neuritis and myelitis. Methods: We reviewed the medical records of 25 cases of relapsing NMO seen at the Ramos Mejia Hospital in Argentina during the period from 2006 to 2010.


Background: Using an anti-aquaporin-4 (AQP4) antibody assay discovered in 2005, Japanese patients with neuromyelitis optica (NMO) can easily be differentially diagnosed from those with opticospinal multiple sclerosis (MS).


Background: Based on case series and anecdotal evidence, immunosuppression has been shown to reduce relapse rates and delay disability in Neuromyelitis Optica spectrum disorders (NMOSD) and is currently the mainstay of disease modifying treatment.


Background: Neuromyelitis optica (NMO) is an inflammatory disorder of the central nervous system predominantly affecting the optic nerves and spinal cord with severe relapses resulting devastating disability.


Neuromyelitis optica (NMO) is an autoimmune disease of the central nervous system characterized by severe demyelinating inflammatory attacks typically affecting the spinal cord and optic nerves. Anti-aquaporin-4(AQP4) serum autoantibodies are present in approximately 70% of NMO patients. Those antibodies probably are pathogenic and the titers are elevated during relapse as compared with those in remission


Neuromyelitis optica (NMO, Devic’s syndrorne.l is characterized by concurrence of optic neuritis and transverse myelitis, typically associated with a lesion in the spinal cord extending over three or more vertebral segments. It is an inflammatory, demyelinating central nervous system disorder, and although it is most commonly relapsing, it is distinct from multiple sclerosis in that it is more severe, tends to spare the brain, and is associated with a longitudinally extensive lesion on spinal cord MRI. Furthermore, NMO is associated with a highly specific serum autoantibody m,1rker, NMO-lgG, which targets the water channel aquaporin-4.


OBJECTIVES: Longitudinal myelitis in patients with Sjogren’s syndrome (SS) is a rarely reported occurrence. Here, we present a patient with longitudinal myelitis who was found to have both primary SS and a positive antibody to aquaporin-4 (NMO-IgG). We review the recent literature concerning the overlap between primary SS-associated myelitis and the presence of NMO-IgG, suggestive of a neuromyelitis optica spectrum disorder (NMOSD).


OBJECTIVE: To describe a patient with neuromyelitis optica (NMO) whose aquaporin 4 (AQP4) antibody levels increased following treatment with interferon beta. DESIGN: Prospective clinical and laboratory case report. SETTING: Institutional referral center for multiple sclerosis (MS)